



d-24-03

CE/1600
RECEIVED
JAN 28 2003
PATENT CENTER 1600/2900
#28
Dmt
23-3

Attorney Docket No. GENENT.065A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DeSavage et al.

App. No.: 09/272,835

Filed: March 19, 1999

Confirmation Number: 6145

For: GRF03 AND ITS USES

Art Unit: 1647

Examiner: Robert Hayes

Customer Number: 25213

Express Mail Label No. EV 194 297 910 US; January 22, 2003

REQUEST FOR CONTINUED EXAMINATION

Box RCE

Commissioner for Patents

Washington, D.C. 20231

Sir:

This is a Request for Continued Examination under 37 CFR 1.114 of the above-entitled patent application, including the following:

1. Response to Office Action
2. A stamped, self-addressed return postcard

Fee

[X] RCE fee 750.00
TOTAL FEE DUE: \$750.00
[X] A check for \$750.00 is enclosed.

Deposit Account Authorization

[X] Please charge any additional fees that may be required, or credit any overpayment to Deposit Account No. 08-1641, referring to GENENT.065A. This is not, however, an authorization to pay the issue fee. A duplicate of this document is enclosed.

Respectfully submitted,


James A. Fox
Attorney for Applicant
Reg. No. 38,455

01/27/2003 AWONDAF1 00000094 09272835

01 FC:1801

750.00 DP

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park CA 94025-3506
(650) 324-6951



GEN. INT. 065A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 28 2003
TECH CENTER 3500/2900

#29/6
DMT
2-3-03

Applicant : DeSavauge et al.)
Appl. No. : 09/272,835)
Filed : March 19, 1999)
For : GRF α 3 AND ITS USES)
Examiner : Robert Hayes)

Group Art Unit 1647

Customer No. 25213

Express Mail Label No.:

EV 194 297 910 US

Mailed in Menlo Park, CA on:

January 22, 2003

Box RCE
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

The present Preliminary Amendment is filed concurrently with filing a Request for Continued Examination of the above indicated application. Prior to issuance of an Office Action, please enter the following amendment and consider the following remarks. The following amendment and remarks assume that the amendment received in the Patent and Trademark Office on October 1, 2002 was entered.

In the Claims:

Please cancel claims 72, 73, 77, 81, and 85.

Please add the following new claims:

86. An isolated nucleic acid molecule comprising a nucleic acid encoding a polypeptide having at least 80% sequence identity with amino acid residues 27 to 374 of the native sequence murine GFR α 3 polypeptide of Figures 1A-B (SEQ ID NO: 5), and having the ability to regulate peripheral neuronal function.

21